Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Health Information Technology and Healthcare Information System01:30

Health Information Technology and Healthcare Information System

Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Wastewater Surveillance for SARS-CoV-2 in Rural Kentucky, 2021-2023.

Viruses·2026
Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results.

Nature cancer·2026
Same journal

Hepatitis C Virus Cascade of Care in Florida Emergency Departments.

Medical care·2026
Same journal

Association of Neighborhood Socioeconomic Disadvantage and Uptake of Diabetes Prevention Interventions.

Medical care·2026
Same journal

Machine Learning for Evaluating the Heterogeneous Effects of Intensive In-Hospital Rehabilitation During the Postacute Phase After Hip Fracture Surgery on Activities of Daily Living.

Medical care·2026
Same journal

Hospital-Physician Integration and Differences in the Use of Orthopedic Care Across Race and Ethnicity.

Medical care·2026
Same journal

Temporal Misalignment and Selection Bias in "Burn Pit Smoke Exposure and Sleep Apnea in US Veterans.

Medical care·2026
Same journal

The Impact of an Oncology Hospital at Home Program on Health Care Costs.

Medical care·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Bayesian meta-analyses for comparative effectiveness and informing coverage decisions.

Scott M Berry1, K Jack Ishak, Bryan R Luce

  • 1Berry Consultants, College Station, TX 77845, USA. scott@berryconsultants.com

Medical Care
|May 18, 2010
PubMed
Summary
This summary is machine-generated.

Bayesian meta-analyses of implantable cardioverter defibrillator trials show high probability of benefit. This approach effectively informs health policy and predicts future trial outcomes.

More Related Videos

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Experiment Videos

Last Updated: Jun 13, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Area of Science:

  • Medical Statistics
  • Health Technology Assessment
  • Clinical Trial Analysis

Background:

  • Evidence-based medicine is crucial for healthcare decision-making.
  • Bayesian techniques are being explored for evidence synthesis by policymakers.
  • A case study analyzed implantable cardioverter defibrillator trials using patient-level data.

Purpose of the Study:

  • To conduct Bayesian meta-analyses of defibrillator trials using published data.
  • To demonstrate a Bayesian approach valuable for policy decisions.
  • To model hazard ratios and perform sequential meta-analyses over time.

Main Methods:

  • Reanalyzed trials from a 2007 systematic review.
  • Extracted data from original published articles.
  • Employed a Bayesian hierarchical model with variants, modeling hazard ratios by follow-up year.

Main Results:

  • The most robust model showed a >0.999 probability of a beneficial mean defibrillator effect.
  • Approximately 5% of trials in the population exhibited detrimental effects.
  • Conclusions remained stable after the first 3 of 12 trials, enabling future trial predictions.

Conclusions:

  • Bayesian meta-analyses from literature can inform coverage decisions.
  • Bayesian modeling can clarify treatment effects on mortality over time.
  • Sequential Bayesian analysis aids in predicting outcomes and assessing future trial utility.